Henlius and Sandoz Enter a Global Collaboration Agreement to Commercialize HLX13 (Biosimilar, Yervoy)
Shots:
- Henlius has granted Sandoz exclusive rights of the HLX13, a biosimilar version of Yervoy (ipilimumab), which is being assessed in a Henlius-led P-I/III trial for inoperable HCC, targeting enrollment of 656 pts
- As per the deal, Sandoz will register & market HLX13 in Australia, Canada, EU, Japan, & the US in exchange for milestone-based payment of ~$301M, incl. $31M upfront post Yervoy patent expiry by Feb 2026 in the EU & Mar 2025 in the US, while Henlius will handle development & manufacturing
- Also, Sandoz is assessing its Opdivo biosimilar in P-I/III trial for advanced melanoma with a target enrollment of 720 pts & expects to launch its denosumab biosimilars, Wyost & Jubbonti, in the US by Q2’25 & EU by Q4’25
Ref: Sandoz | Image: Sandoz & Henlius
Related News:- Shanghai Henlius Biotech and Organon Reports EMA’s Validation of HLX11 (Biosimilar, Perjeta)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
